SG11201910143TA - Combination of a cell therapy and an immunomodulatory compound - Google Patents

Combination of a cell therapy and an immunomodulatory compound

Info

Publication number
SG11201910143TA
SG11201910143TA SG11201910143TA SG11201910143TA SG 11201910143T A SG11201910143T A SG 11201910143TA SG 11201910143T A SG11201910143T A SG 11201910143TA SG 11201910143T A SG11201910143T A SG 11201910143TA
Authority
SG
Singapore
Prior art keywords
cell therapy
international
methods
cells
suite
Prior art date
Application number
Inventor
Michael Ports
Melissa Works
Oleksandr Baturevych
Ruth Salmon
Ronald Hause
Timothy Johnstone
David Kugler
Jon Jones
Neha Soni
Original Assignee
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Juno Therapeutics Inc filed Critical Juno Therapeutics Inc
Publication of SG11201910143TA publication Critical patent/SG11201910143TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/463—Cellular immunotherapy characterised by recombinant expression
    • A61K39/4631—Chimeric Antigen Receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464411—Immunoglobulin superfamily
    • A61K39/464412—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A61K39/464402—Receptors, cell surface antigens or cell surface determinants
    • A61K39/464416—Receptors for cytokines
    • A61K39/464417—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

EAI assay background - .4 a 1500- C) ea 4 3) 1000- o 500- 40• (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 November 2018 (08.11.2018) WI PO I PCT o n ono oIIIDIDIIIIIMD1111010lII1111111 Hs (10) International Publication Number WO 2018/204427 Al (51) International Patent Classification: A61K 35/17 (2015.01) A61P 35/00 (2006.01) A61K 31/454 (2006.01) (21) International Application Number: PCT/US2018/030545 (22) International Filing Date: 01 May 2018 (01.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/492,947 01 May 2017 (01.05.2017) US 62/538,670 29 July 2017 (29.07.2017) US 62/549,390 23 August 2017 (23.08.2017) US 62/580,433 01 November 2017 (01.11.2017) US 62/596,753 08 December 2017 (08.12.2017) US (71) Applicant: JUNO THERAPEUTICS, INC. [US/US]; 400 Dexter Ave. N, Suite 1200, Seattle, WA 98109 (US). (72) Inventors: PORTS, Michael; C/o Juno Therapeutics, Inc., 400 Dexter Ave. N, Suite 1200, Seattle, WA 98109 (US). WORKS, Melissa; C/o Juno Therapeutics, Inc., 400 Dexter Ave. N, Suite 1200, Seattle, WA 98109 (US). (74) Agent: POTTER, Karen et al.; Morrison & Foerster LLP, 12531 High Bluff Drive, Suite 100, San Diego, CA 92130-2040 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, (54) Title: COMBINATION OF A CELL THERAPY AND AN IMMUNOMODULATORY COMPOUND FIG. 1A 2500- N O 00 11 O C (57) : The present disclosure relates in some aspects to methods, compositions and uses involving immunotherapies, such as adoptive cell therapy, e.g., T cell therapy, and an immunomodulatory compound, such as a structural or functional analog or derivative of thalidomide and/or an inhibitor of E3-ubiquitin ligase. The provided methods, compositions and uses include those for combination therapies involving the administration or use of one or more immunomodulatory compounds in conjunction with a T cell therapy, such as a genetically engineered T cell therapy involving cells engineered with a recombinant receptor, such as chimeric antigen receptor (CAR)-expressing T cells. Also provided are compositions, methods of administration to subjects, articles of manufacture and kits for use in the methods. In some aspects, features of the methods and cells provide for increased or improved activity, efficacy, persistence, expansion and/or proliferation of T cells for adoptive cell therapy or endogenous T cells recruited by immunotherapeutic agents. [Continued on next page] WO 2018/204427 Al MIDEDIMOMOIDEIRDERI0010101HOIEMERVOIMIE MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: — with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a))
SG11201910143T 2017-05-01 2018-05-01 Combination of a cell therapy and an immunomodulatory compound SG11201910143TA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201762492947P 2017-05-01 2017-05-01
US201762538670P 2017-07-29 2017-07-29
US201762549390P 2017-08-23 2017-08-23
US201762580433P 2017-11-01 2017-11-01
US201762596753P 2017-12-08 2017-12-08
PCT/US2018/030545 WO2018204427A1 (en) 2017-05-01 2018-05-01 Combination of a cell therapy and an immunomodulatory compound

Publications (1)

Publication Number Publication Date
SG11201910143TA true SG11201910143TA (en) 2019-11-28

Family

ID=62563245

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201910143T SG11201910143TA (en) 2017-05-01 2018-05-01 Combination of a cell therapy and an immunomodulatory compound

Country Status (18)

Country Link
US (1) US20200078404A1 (en)
EP (2) EP4327878A2 (en)
JP (2) JP7299841B2 (en)
KR (1) KR20200026805A (en)
CN (1) CN111182909A (en)
AU (1) AU2018263887A1 (en)
BR (1) BR112019022893A2 (en)
CA (1) CA3061945A1 (en)
DK (1) DK3618842T3 (en)
FI (1) FI3618842T3 (en)
IL (2) IL310031A (en)
MA (1) MA51871A (en)
MX (1) MX2019012975A (en)
PH (1) PH12019502470A1 (en)
PL (1) PL3618842T3 (en)
PT (1) PT3618842T (en)
SG (1) SG11201910143TA (en)
WO (1) WO2018204427A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ732568A (en) 2014-12-05 2023-03-31 Memorial Sloan Kettering Cancer Center Antibodies targeting b-cell maturation antigen and methods of use
MX2019008227A (en) 2017-01-10 2020-08-17 Juno Therapeutics Inc Epigenetic analysis of cell therapy and related methods.
MX2019009552A (en) 2017-02-17 2019-10-02 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders.
US20200254093A1 (en) * 2017-09-14 2020-08-13 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer
WO2019090003A1 (en) 2017-11-01 2019-05-09 Juno Therapeutics, Inc. Chimeric antigen receptors specific for b-cell maturation antigen (bcma)
MA49911A (en) * 2017-11-01 2020-06-24 Juno Therapeutics Inc ANTIBODIES AND CHEMERICAL ANTIGENIC RECEPTORS SPECIFIC TO THE B-LYMPHOCYTE MATURATION ANTIGEN
US11851679B2 (en) 2017-11-01 2023-12-26 Juno Therapeutics, Inc. Method of assessing activity of recombinant antigen receptors
CN113573719A (en) * 2018-11-08 2021-10-29 朱诺治疗学股份有限公司 Methods and combinations of therapy and T cell modulation
EP3958875A4 (en) * 2019-04-25 2023-05-10 Purdue Research Foundation Engineered natural killer cells redirected toward purinergic signaling, constructs thereof, and methods for using the same
JP2022554348A (en) 2019-11-05 2022-12-28 ジュノー セラピューティクス インコーポレイテッド Methods of Determining Attributes of Therapeutic T Cell Compositions
EP4054623A1 (en) * 2019-11-07 2022-09-14 Juno Therapeutics, Inc. Combination of a t cell therapy and (s)-3-[4-(4-morpholin-4 ylmethyl-benzyloxy)-l-oxo-l,3-dihydro-isoindol-2-yl]- piperidine-2,6-dione
WO2021148019A1 (en) * 2020-01-22 2021-07-29 科济生物医药（上海）有限公司 Method for transducing cells with viral vector
MX2022009830A (en) * 2020-02-12 2022-10-28 Juno Therapeutics Inc Bcma-directed chimeric antigen receptor t cell compositions and methods and uses thereof.
KR20230024283A (en) 2020-05-13 2023-02-20 주노 쎄러퓨티크스 인코퍼레이티드 Methods for identifying features associated with clinical response and uses thereof
WO2022137181A1 (en) * 2020-12-23 2022-06-30 Crispr Therapeutics Ag Co-use of lenalidomide with car-t cells
CN113087798B (en) * 2020-12-31 2022-05-24 北京艺妙神州医药科技有限公司 anti-BCMA antibody and application thereof
AU2022316980A1 (en) * 2021-07-29 2024-01-25 Takeda Pharmaceutical Company Limited Car-expressing immune cells that specifically target mesothelin and uses thereof
WO2023230548A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Method for predicting response to a t cell therapy

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
AU4746590A (en) 1988-12-28 1990-08-01 Stefan Miltenyi Methods and materials for high gradient magnetic separation of biological materials
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5629327A (en) 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
WO1996013593A2 (en) 1994-10-26 1996-05-09 Procept, Inc. Soluble single chain t cell receptors
WO1996018105A1 (en) 1994-12-06 1996-06-13 The President And Fellows Of Harvard College Single chain t-cell receptor
DE19608753C1 (en) 1996-03-06 1997-06-26 Medigene Gmbh Transduction system based on rep-negative adeno-associated virus vector
WO1997034634A1 (en) 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
HU228769B1 (en) 1996-07-24 2013-05-28 Celgene Corp Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
US6281230B1 (en) 1996-07-24 2001-08-28 Celgene Corporation Isoindolines, method of use, and pharmaceutical compositions
ES2529190T3 (en) 1996-07-24 2015-02-17 Celgene Corporation 2- (2,6-Dioxopiperidin-3-yl) -amino-substituted phthalimides to reduce TNF-alpha levels
US5635517B1 (en) 1996-07-24 1999-06-29 Celgene Corp Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines
US5798368A (en) 1996-08-22 1998-08-25 Celgene Corporation Tetrasubstituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines and method of reducing TNFα levels
CA2305630C (en) 1997-10-02 2012-11-06 Sunol Molecular Corporation Soluble single-chain t-cell receptor proteins
HUP0102113A3 (en) 1998-03-16 2003-03-28 Celgene Corp Warren 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
HUP0103614A2 (en) 1998-05-19 2002-01-28 Avidex Limited Soluble t cell receptor
CA2343156A1 (en) 1998-09-04 2000-03-16 Sloan-Kettering Institute For Cancer Research Fusion receptors specific for prostate-specific membrane antigen and uses thereof
US6410319B1 (en) 1998-10-20 2002-06-25 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
ES2250121T3 (en) 1999-03-18 2006-04-16 Celgene Corporation 1-OXO- AND 1,3-DIOXOISOINDOLINAS AND ITS EMPLOYMENT IN PHARMACEUTICAL COMPOSITIONS FOR THE REDUCTION OF LEVELS OF INFLAMMATORY CITOCINES.
AU2001265346A1 (en) 2000-06-02 2001-12-17 Memorial Sloan-Kettering Cancer Center Artificial antigen presenting cells and methods of use thereof
ATE338124T1 (en) 2000-11-07 2006-09-15 Hope City CD19-SPECIFIC TARGETED IMMUNE CELLS
US6458810B1 (en) 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US7091353B2 (en) 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
US20030045552A1 (en) 2000-12-27 2003-03-06 Robarge Michael J. Isoindole-imide compounds, compositions, and uses thereof
ES2338534T3 (en) 2001-02-27 2010-05-10 The Governement Of The Usa, Represented By The Secretary Department Of Health And Human Services TALIDOMINE ANALOGS AS INHIBITORS OF ANGIOGENESIS.
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7329731B2 (en) 2001-08-31 2008-02-12 Medigene Limited Soluble T cell receptor
US7939059B2 (en) 2001-12-10 2011-05-10 California Institute Of Technology Method for the generation of antigen-specific lymphocytes
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
EP1549748B1 (en) 2002-10-09 2014-10-01 Immunocore Ltd. Single chain recombinant t cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
DE602005022595D1 (en) 2004-06-29 2010-09-09 Immunocore Ltd A MODIFIED T-CELL RECEPTOR EXPRESSING CELLS
US7244759B2 (en) 2004-07-28 2007-07-17 Celgene Corporation Isoindoline compounds and methods of making and using the same
EP2856876B1 (en) 2007-03-30 2018-01-31 Memorial Sloan-Kettering Cancer Center Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
US7615883B2 (en) 2007-06-06 2009-11-10 Meheen H Joe Wind driven venturi turbine
ES2374863T3 (en) 2007-12-07 2012-02-22 Miltenyi Biotec Gmbh CENTRIFUGAL TO SEPARATE A SAMPLE IN AT LEAST TWO COMPONENTS.
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (en) 2008-05-27 2013-04-03 キヤノン株式会社 Management apparatus, image forming apparatus, and processing method thereof
HUE058891T2 (en) 2008-08-26 2022-09-28 Hope City Method and compositions for enhanced anti-tumor effector functioning of t cells
NZ612647A (en) 2009-03-10 2015-03-27 Biogen Idec Inc Anti-bcma antibodies
EP2486049A1 (en) 2009-10-06 2012-08-15 The Board Of Trustees Of The UniversityOf Illinois Human single-chain t cell receptors
EP2496698B1 (en) 2009-11-03 2019-01-09 City of Hope TRUNCATED EPIDERIMAL GROWTH FACTOR RECEPTOR (EGFRt) FOR TRANSDUCED T CELL SELECTION
LT2649086T (en) 2010-12-09 2017-11-10 The Trustees Of The University Of Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
MX359513B (en) 2011-03-23 2018-10-01 Hutchinson Fred Cancer Res METHOD and COMPOSITIONS FOR CELLULAR IMMUNOTHERAPY.
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
CA2855358C (en) 2011-11-11 2021-03-16 Fred Hutchinson Cancer Research Center Cyclin a1-targeted t-cell immunotherapy for cancer
AU2013221672B2 (en) 2012-02-13 2017-11-09 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2013126726A1 (en) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Double transgenic t cells comprising a car and a tcr and their methods of use
KR20210032014A (en) 2012-04-11 2021-03-23 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 Chimeric antigen receptors targeting b-cell maturation antigen
JP6251734B2 (en) 2012-05-03 2017-12-27 フレッド ハッチンソン キャンサー リサーチ センター Affinity enhanced T cell receptor and method for producing the same
KR102264290B1 (en) 2012-08-20 2021-06-10 프레드 헛친슨 켄서 리서치 센터 Method and compositions for cellular immunotherapy
SG11201502598SA (en) 2012-10-02 2015-05-28 Sloan Kettering Inst Cancer Compositions and methods for immunotherapy
WO2014097442A1 (en) 2012-12-20 2014-06-26 三菱電機株式会社 On-board device, and program
UY35468A (en) 2013-03-16 2014-10-31 Novartis Ag CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus
CA3206268A1 (en) 2013-12-06 2015-06-11 Celgene Corporation Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
ES2767423T3 (en) 2014-01-13 2020-06-17 Hope City Chimeric antigen receptors (CARS) with mutations in the Fc spacer region and methods for their use
EP3129470B1 (en) * 2014-04-07 2021-04-07 Novartis Ag Treatment of cancer using anti-cd19 chimeric antigen receptor
DK3166968T3 (en) 2014-05-02 2021-12-06 Univ Pennsylvania Compositions and Methods for Chimeric Autoantibody Receptor T Cells
EP3193915A1 (en) * 2014-07-21 2017-07-26 Novartis AG Combinations of low, immune enhancing. doses of mtor inhibitors and cars
CN106795217B (en) 2014-07-24 2021-08-06 蓝鸟生物公司 BCMA chimeric antigen receptors
CN107111299B (en) 2014-09-22 2021-02-05 伊莫拉Sacmi机械合作公司 Production line for producing single products in succession in a continuous cycle
SG11201704549UA (en) 2014-12-05 2017-07-28 Memorial Sloan Kettering Cancer Center Chimeric antigen receptors targeting b-cell maturation antigen and uses thereof
NZ732568A (en) 2014-12-05 2023-03-31 Memorial Sloan Kettering Cancer Center Antibodies targeting b-cell maturation antigen and methods of use
US10383929B2 (en) 2014-12-12 2019-08-20 Bluebird Bio, Inc. BCMA chimeric antigen receptors
US9713375B1 (en) 2015-02-26 2017-07-25 Brett Einar Rahm Collapsible portable table
ES2876974T3 (en) * 2015-04-07 2021-11-15 Novartis Ag Combination therapy with chimeric antigen receptor and amino pyrimidine derivatives
EP3466967A1 (en) 2015-05-18 2019-04-10 TCR2 Therapeutics Inc. Compositions and methods for tcr reprogramming using fusion proteins
WO2016210262A1 (en) * 2015-06-26 2016-12-29 Celgene Corporation Methods for the treatment of kaposi's sarcoma or kshv-induced lymphoma using immunomodulatory compounds, and uses of biomarkers
CN105384825B (en) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 A kind of bispecific chimeric antigen receptor and its application based on single domain antibody
WO2017058754A1 (en) * 2015-09-28 2017-04-06 Celgene Corporation Combination therapy for treatment of hematological cancers and solid tumors
AU2017240667C1 (en) 2016-04-01 2022-11-24 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
KR20190084053A (en) * 2016-10-13 2019-07-15 주노 쎄러퓨티크스 인코퍼레이티드 Methods and compositions for immune therapy involving tryptophan pathway regulators
CN109983027A (en) * 2016-10-20 2019-07-05 细胞基因公司 Based on CEREBLON can heterodimerization Chimeric antigen receptor
MA46716A (en) * 2016-11-03 2019-09-11 Juno Therapeutics Inc CELL THERAPY AND MICROGLIA INHIBITOR POLYTHERAPY
MX2019005029A (en) * 2016-11-03 2019-10-24 Juno Therapeutics Inc Combination therapy of a t cell therapy and a btk inhibitor.
BR112019011065A2 (en) * 2016-12-03 2019-10-01 Juno Therapeutics Inc methods for determining car cell dosage
EP3548046A2 (en) * 2016-12-03 2019-10-09 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
EP3548083A1 (en) * 2016-12-03 2019-10-09 Juno Therapeutics, Inc. Methods for modulation of car-t cells
CN109752300A (en) 2019-01-02 2019-05-14 五邑大学 A kind of coating material production safe and intelligent crusing robot, system and method

Also Published As

Publication number Publication date
RU2019138707A3 (en) 2021-12-21
PH12019502470A1 (en) 2021-01-11
US20200078404A1 (en) 2020-03-12
IL310031A (en) 2024-03-01
BR112019022893A2 (en) 2020-05-19
AU2018263887A1 (en) 2019-11-21
JP2020518591A (en) 2020-06-25
CN111182909A (en) 2020-05-19
KR20200026805A (en) 2020-03-11
JP7299841B2 (en) 2023-06-28
WO2018204427A1 (en) 2018-11-08
RU2019138707A (en) 2021-06-02
PT3618842T (en) 2024-01-12
EP3618842B1 (en) 2023-10-18
FI3618842T3 (en) 2023-12-15
EP3618842A1 (en) 2020-03-11
DK3618842T3 (en) 2024-01-02
PL3618842T3 (en) 2024-02-19
IL270250B1 (en) 2024-02-01
MA51871A (en) 2020-03-11
EP4327878A2 (en) 2024-02-28
IL270250A (en) 2019-12-31
MX2019012975A (en) 2020-08-03
CA3061945A1 (en) 2018-11-08
JP2023116720A (en) 2023-08-22

Similar Documents

Publication Publication Date Title
SG11201910143TA (en) Combination of a cell therapy and an immunomodulatory compound
SG11201900885VA (en) Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201908719QA (en) Biomarkers and car t cell therapies with enhanced efficacy
SG11201903282TA (en) Immunotherapy methods and compositions involving tryptophan metabolic pathway modulators
SG11201809912UA (en) Hybrid carriers for nucleic acid cargo
SG11201807187XA (en) Binding members to pd-l1
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201909949XA (en) Targeted immunotolerance
SG11201900480YA (en) Anti-tim-3 antibodies
SG11201907561PA (en) Anti-lag-3 antibodies and uses thereof
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201811290VA (en) Compositions and methods for the depletion of cd117+cells
SG11201903454VA (en) Immunologically discernible cell surface variants for use in cell therapy
SG11201811432WA (en) Rna for cancer therapy
SG11201901642XA (en) Constitutively active cytokine receptors for cell therapy
SG11201806583XA (en) Compositions containing tucaresol or its analogs
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201902938TA (en) Compounds, devices, and uses thereof
SG11201811363YA (en) Anti-zika virus antibodies and methods of use
SG11201407580YA (en) Composition comprising two antibodies engineered to have reduced and increased effector function
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201900200XA (en) Tgfb antibodies, methods, and uses
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201808710UA (en) Novel immunogenic cd1d binding peptides